



29 June 2021

Sydney, Australia

## Cleansing Statement

**Sydney, 29 June 2021:** Nyrada Inc (ASX: NYR), issued further to two Appendix 2As and an Appendix 3G lodged on 29 June 2021:

- 14,601,287 CHESS Depository Interests (CDIs) from Tranche 2 of Capital Raising Program as announced on 22 March 2021 and as approved by holders on 16 June 2021 (Resolution 3);
- 951,923 CHESS Depository Interests (CDIs) from the Capital Raising Program as approved by holders on 16 June 2021 (Resolution 4);
- 654,231 CHESS Depository Interests (CDIs) from the Capital Raising Program as announced on 22 March 2021 and as approved by holders on 16 June 2021 (Resolution 5);
- 1,269,231 CHESS Depository Interests (CDIs) from the Capital Raising Program to Directors as announced on 22 March 2021 and as approved by holders on 16 June 2021 (Resolutions 9 – 14 inclusive); and
- 8,000,000 Unlisted Options from the Capital Raising Program as announced on 22 March 2021 and as approved by holders on 16 June 2021 (Resolutions 6-8 inclusive).

NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The CDIs and Unlisted Options were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NYR has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in black ink, appearing to read 'D Franks'.

David Franks

Company Secretary



## About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.*

### Investor & Corporate Enquiries:

Laura Vize  
Investor Relations Manager  
T: 0417 026 056  
E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks  
T: 02 8072 1400  
E: [David.Franks@atomicgroup.com.au](mailto:David.Franks@atomicgroup.com.au)

### Media Enquiries:

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.